Hyperthermic intraperitoneal chemotherapy in interval debulking surgery for advanced epithelial ovarian cancer: A single-center, real-life experience.
Valentina GhirardiCarlo RonsiniRita TrozziChiara Di IlioAndrea Di GiorgioStefano CianciGaetano DraisciGiovanni ScambiaAnna FagottiPublished in: Cancer (2020)
In the authors' experience, the addition of HIPEC to IDS is feasible in 35% for the population. This value might increase with changes in the inclusion/exclusion criteria. HIPEC does not increase perioperative complications and does not affect a patient's recovery or time to start adjuvant chemotherapy. HIPEC should be offered to select patients listed for IDS.
Keyphrases
- end stage renal disease
- ejection fraction
- newly diagnosed
- minimally invasive
- chronic kidney disease
- prognostic factors
- neoadjuvant chemotherapy
- patients undergoing
- risk factors
- squamous cell carcinoma
- cardiac surgery
- coronary artery bypass
- locally advanced
- radiation therapy
- acute coronary syndrome
- atrial fibrillation
- chemotherapy induced